SCHEMBL19798468

SCHEMBL19798468

O=C(Cc1ccccc1)N1C2CC3CC(C2)CC1C3

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.57
HPGD P15428 2/20 0.57
GLA P06280 1/20 0.57
CHRM2 P08172 1/20 0.51
CHRM4 P08173 1/20 0.51
CHRM5 P08912 1/20 0.51
KDM4E B2RXH2 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TACR3 P29371 1/20 0.45
POLB P06746 1/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
AKR1B1 P15121 1/20 0.45
HSD11B1 P28845 2/20 0.45
OPRK1 P41145 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15955727 0.80 ALDH1A1 (0.44) ALDH1A1HPGDGLACHRM2CHRM4
SCHEMBL20724773 0.78 ALDH1A1 (0.52) ALDH1A1HPGDGLAKDM4EL3MBTL1
SCHEMBL20724777 0.78 ALDH1A1 (0.52) ALDH1A1HPGDGLAKDM4EL3MBTL1
SCHEMBL699162 0.74 CHRNB2 (0.56) ALDH1A1HPGDCHRM2CHRM4CHRM5
SCHEMBL19386635 0.73 ALDH1A1 (0.58) ALDH1A1HPGDGLAKDM4EL3MBTL1
SCHEMBL27434790 0.72 ALDH1A1 (1.00) ALDH1A1HPGDGLACHRM2CHRM4
SCHEMBL1714058 0.72 ALDH1A1 (0.71) ALDH1A1HPGDGLAKDM4EL3MBTL1
SCHEMBL10722408 0.71 HSD11B1 (0.77) ALDH1A1HPGDKDM4EL3MBTL1HSD11B1
SCHEMBL3967794 0.71 HSD11B1 (0.77) ALDH1A1HPGDKDM4EL3MBTL1HSD11B1
SCHEMBL4113820 0.70 ALDH1A1 (0.68) ALDH1A1HPGDGLAKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202388-B2 Fused-ring compounds, pharmaceutical composition and uses thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2019-02-12 US disclosed
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-01-25 US disclosed
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202388-B2 Fused-ring compounds, pharmaceutical composition and uses thereof IDO1, IDO2, TDO2 ALDH1A1 2128/4885HPGD 635/4885GLA 2293/4885
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF IDO1, IDO2, TDO2 ALDH1A1 2128/4885HPGD 635/4885GLA 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.